The Korean Journal of Medicine

The Korean Association of Internal Medicine (대한내과학회)
권호 표지
DOI QR코드

DOI QR Code

Infection Prevention in Transplant Recipients

이식 환자의 감염 예방

  • Ha, Young Eun (Division of Infectious Diseases, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Peck, Kyong Ran (Division of Infectious Diseases, Samsung Medical Center, Sungkyunkwan University School of Medicine)
  • 하영은 (성균관대학교 의과대학 삼성서울병원 감염내과) ;
  • 백경란 (성균관대학교 의과대학 삼성서울병원 감염내과)
  • Published : 2013.02.01
⟨ Previous Next ⟩

Abstract

Opportunistic infections are major causes of morbidity and mortality in hematopoietic stem-cell transplant and solid organ transplant recipients. The epidemiology and incidence of opportunistic infections in those patients have been dramatically changed with use of potent immunosuppressive agents as well as routine prophylaxis against various microorganisms such as common bacterial pathogens, fungi, cytomegalovirus, Pneumocystis jirovecii, and so on. Because transplant recipients are at the greatest risk for infection during early phase (1-3 months) after transplant, safe and effective prevention strategies should be implemented in this period. Moreover, beyond early phase, recipients are often susceptible to infections due to prolonged immunosuppressive therapy for graft rejection or chronic graft-versus-host diseases. Therefore, clinicians should assess a recipient's risk of infection on the basis of concomitant graft function, intensity of immunosuppression, and other factors that may contribute to susceptibility to infections. We discussed infection prevention strategies among recipients of hematopoietic stem-cell and solid organ transplantation against various opportunistic pathogens. Vaccinations should also be recommended for pre-transplant candidates and post-transplant recipients for the best prevention of infections.

Keywords

References

  1. Fishman JA. Infection in solid-organ transplant recipients. N Engl J Med 2007;357:2601-2614. https://doi.org/10.1056/NEJMra064928
  2. Tomblyn M, Chiller T, Einsele H, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant 2009;15:1143-1238. https://doi.org/10.1016/j.bbmt.2009.06.019
  3. Lee DG, Kim SH, Kim SY, et al. Evidence-based guidelines for empirical therapy of neutropenic fever in Korea. Infect Chemother 2011;43:258-321.
  4. Goodrich JM, Bowden RA, Fisher L, Keller C, Schoch G, Meyers JD. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann Intern Med 1993;118:173-178. https://doi.org/10.7326/0003-4819-118-3-199302010-00003
  5. Prentice HG, Gluckman E, Powles RL, et al. Impact of long-term acyclovir on cytomegalovirus infection and survival after allogeneic bone marrow transplantation: European Acyclovir for CMV Prophylaxis Study Group. Lancet 1994;343:749-753. https://doi.org/10.1016/S0140-6736(94)91835-X
  6. Ljungman P, de La Camara R, Milpied N, et al. Randomized study of valacyclovir as prophylaxis against cytomegalovirus reactivation in recipients of allogeneic bone marrow transplants. Blood 2002;99:3050-3056. https://doi.org/10.1182/blood.V99.8.3050
  7. Boeckh M, Nichols WG, Papanicolaou G, Rubin R, Wingard JR, Zaia J. Cytomegalovirus in hematopoietic stem cell transplant recipients: current status, known challenges, and future strategies. Biol Blood Marrow Transplant 2003; 9:543-558. https://doi.org/10.1016/S1083-8791(03)00287-8
  8. Drew WL. Laboratory diagnosis of cytomegalovirus infection and disease in immunocompromised patients. Curr Opin Infect Dis 2007;20:408-411. https://doi.org/10.1097/QCO.0b013e32821f6010
  9. Tomblyn M, Chiller T, Einsele H, et al. Guidelines for preventing infectious complications among hematopoietic cell transplant recipients: a global perspective: preface. Bone Marrow Transplant 2009;44:453-455. https://doi.org/10.1038/bmt.2009.254
  10. Freeman RB. Valganciclovir: oral prevention and treatment of cytomegalovirus in the immunocompromised host. Expert Opin Pharmacother 2004;5:2007-2016. https://doi.org/10.1517/14656566.5.9.2007
  11. Ayala E, Greene J, Sandin R, et al. Valganciclovir is safe and effective as pre-emptive therapy for CMV infection in allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2006;37:851-856. https://doi.org/10.1038/sj.bmt.1705341
  12. Einsele H, Reusser P, Bornhäuser M, et al. Oral valganciclovir leads to higher exposure to ganciclovir than intravenous ganciclovir in patients following allogeneic stem cell transplantation. Blood 2006;107:3002-3008. https://doi.org/10.1182/blood-2005-09-3786
  13. Van der Heiden PL, Kalpoe JS, Barge RM, Willemze R, Kroes AC, Schippers EF. Oral valganciclovir as pre-emptive therapy has similar efficacy on cytomegalovirus DNA load reduction as intravenous ganciclovir in allogeneic stem cell transplantation recipients. Bone Marrow Transplant 2006; 37:693-698. https://doi.org/10.1038/sj.bmt.1705311
  14. Busca A, de Fabritiis P, Ghisetti V, et al. Oral valganciclovir as preemptive therapy for cytomegalovirus infection post allogeneic stem cell transplantation. Transpl Infect Dis 2007;9:102-107. https://doi.org/10.1111/j.1399-3062.2006.00183.x
  15. Allice T, Busca A, Locatelli F, Falda M, Pittaluga F, Ghisetti V. Valganciclovir as pre-emptive therapy for cytomegalovirus infection post-allogenic stem cell transplantation: implications for the emergence of drug-resistant cytomegalovirus. J Antimicrob Chemother 2009;63:600-608. https://doi.org/10.1093/jac/dkn521
  16. Takenaka K, Nagafuji K, Takase K, et al. Initial low-dose valganciclovir as a preemptive therapy is effective for cytomegalovirus infection in allogeneic hematopoietic stem cell transplant recipients. Int J Hematol 2012;96:94-100. https://doi.org/10.1007/s12185-012-1087-9
  17. Nichols WG, Price TH, Gooley T, Corey L, Boeckh M. Transfusion-transmitted cytomegalovirus infection after receipt of leukoreduced blood products. Blood 2003;101: 4195-4200. https://doi.org/10.1182/blood-2002-10-3143
  18. Ljungman P, Larsson K, Kumlien G, et al. Leukocyte depleted, unscreened blood products give a low risk for CMV infection and disease in CMV seronegative allogeneic stem cell transplant recipients with seronegative stem cell donors. Scand J Infect Dis 2002;34:347-350. https://doi.org/10.1080/00365540110080412
  19. Bowden RA, Slichter SJ, Sayers M, et al. A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion- associated CMV infection after marrow transplant. Blood 1995;86:3598-3603.
  20. Ratko TA, Cummings JP, Oberman HA, et al. Evidencebased recommendations for the use of WBC-reduced cellular blood components. Transfusion 2001;41:1310-1319. https://doi.org/10.1046/j.1537-2995.2001.41101310.x
  21. Bowden RA, Slichter SJ, Sayers MH, Mori M, Cays MJ, Meyers JD. Use of leukocyte-depleted platelets and cytomegalovirus- seronegative red blood cells for prevention of primary cytomegalovirus infection after marrow transplant. Blood 1991;78:246-250.
  22. Van Prooijen HC, Visser JJ, van Oostendorp WR, de Gast GC, Verdonck LF. Prevention of primary transfusionassociated cytomegalovirus infection in bone marrow transplant recipients by the removal of white cells from blood components with high-affinity filters. Br J Haematol 1994;87:144-147.
  23. Small LN, Lau J, Snydman DR. Preventing post-organ transplantation cytomegalovirus disease with ganciclovir: a meta-analysis comparing prophylactic and preemptive therapies. Clin Infect Dis 2006;43:869-880. https://doi.org/10.1086/507337
  24. Potena L, Grigioni F, Magnani G, et al. Prophylaxis versus preemptive anti-cytomegalovirus approach for prevention of allograft vasculopathy in heart transplant recipients. J Heart Lung Transplant 2009;28:461-467. https://doi.org/10.1016/j.healun.2009.02.009
  25. Potena L, Valantine HA. Cytomegalovirus-associated allograft rejection in heart transplant patients. Curr Opin Infect Dis 2007;20:425-431. https://doi.org/10.1097/QCO.0b013e328259c33b
  26. Kotton CN, Kumar D, Caliendo AM, et al. International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation 2010;89:779-795. https://doi.org/10.1097/TP.0b013e3181cee42f
  27. Kalil AC, Freifeld AG, Lyden ER, Stoner JA. Valganciclovir for cytomegalovirus prevention in solid organ transplant patients: an evidence-based reassessment of safety and efficacy. PLoS One 2009;4:e5512. https://doi.org/10.1371/journal.pone.0005512
  28. Andrews PA, Emery VC, Newstead C. Summary of the British transplantation society guidelines for the prevention and management of CMV disease after solid organ transplantation. Transplantation 2011;92:1181-1187. https://doi.org/10.1097/TP.0b013e318235c7fc
  29. Kalil AC, Mindru C, Florescu DF. Effectiveness of valganciclovir 900 mg versus 450 mg for cytomegalovirus prophylaxis in transplantation: direct and indirect treatment comparison meta-analysis. Clin Infect Dis 2011;52:313-321. https://doi.org/10.1093/cid/ciq143
  30. Dignani MC, Mykietiuk A, Michelet M, et al. Valacyclovir prophylaxis for the prevention of Herpes simplex virus reactivation in recipients of progenitor cells transplantation. Bone Marrow Transplant 2002;29:263-267. https://doi.org/10.1038/sj.bmt.1703354
  31. Eisen D, Essell J, Broun ER, Sigmund D, DeVoe M. Clinical utility of oral valacyclovir compared with oral acyclovir for the prevention of herpes simplex virus mucositis following autologous bone marrow transplantation or stem cell rescue therapy. Bone Marrow Transplant 2003;31:51-55. https://doi.org/10.1038/sj.bmt.1703817
  32. De Boer MG, Bruijnesteijn van Coppenraet LE, Gaasbeek A, et al. An outbreak of Pneumocystis jiroveci pneumonia with 1 predominant genotype among renal transplant recipients: interhuman transmission or a common environmental source? Clin Infect Dis 2007;44:1143-1149. https://doi.org/10.1086/513198
  33. Schmoldt S, Schuhegger R, Wendler T, et al. Molecular evidence of nosocomial Pneumocystis jirovecii transmission among 16 patients after kidney transplantation. J Clin Microbiol 2008;46:966-971. https://doi.org/10.1128/JCM.02016-07
  34. Sassi M, Ripamonti C, Mueller NJ, et al. Outbreaks of Pneumocystis pneumonia in 2 renal transplant centers linked to a single strain of Pneumocystis: implications for transmission and virulence. Clin Infect Dis 2012;54: 1437-1444. https://doi.org/10.1093/cid/cis217
  35. Phipps LM, Chen SC, Kable K, et al. Nosocomial Pneumocystis jirovecii pneumonia: lessons from a cluster in kidney transplant recipients. Transplantation 2011;92: 1327-1334. https://doi.org/10.1097/TP.0b013e3182384b57
  36. Fishman JA. Prevention of infection due to Pneumocystis carinii. Antimicrob Agents Chemother 1998;42:995-1004.
  37. De Castro N, Neuville S, Sarfati C, et al. Occurrence of Pneumocystis jiroveci pneumonia after allogeneic stem cell transplantation: a 6-year retrospective study. Bone Marrow Transplant 2005;36:879-883. https://doi.org/10.1038/sj.bmt.1705149
  38. Rodriguez M, Fishman JA. Prevention of infection due to Pneumocystis spp. in human immunodeficiency virusnegative immunocompromised patients. Clin Microbiol Rev 2004;17:770-782. https://doi.org/10.1128/CMR.17.4.770-782.2004
  39. Centers for Disease Control and Prevention; Infectious Disease Society of America; American Society of Blood and Marrow Transplantation. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. MMWR Recomm Rep 2000;49(RR-10): 1-125, CE1-7.
  40. Lyytikainen O, Ruutu T, Volin L, et al. Late onset Pneumocystis carinii pneumonia following allogeneic bone marrow transplantation. Bone Marrow Transplant 1996;17: 1057-1059.
  41. Tuan IZ, Dennison D, Weisdorf DJ. Pneumocystis carinii pneumonitis following bone marrow transplantation. Bone Marrow Transplant 1992;10:267-272.
  42. Martin SI, Fishman JA; AST Infectious Diseases Community of Practice. Pneumocystis pneumonia in solid organ transplant recipients. Am J Transplant 2009;9(Suppl 4): S227-S233. https://doi.org/10.1111/j.1600-6143.2009.02914.x
  43. Fishman JA. Prevention of infection caused by Pneumocystis carinii in transplant recipients. Clin Infect Dis 2001;33:1397-1405. https://doi.org/10.1086/323129
  44. Kontoyiannis DP, Marr KA, Park BJ, et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis 2010;50:1091-1100. https://doi.org/10.1086/651263
  45. Marr KA, Bow E, Chiller T, et al. Fungal infection prevention after hematopoietic cell transplantation. Bone Marrow Transplant 2009;44:483-487. https://doi.org/10.1038/bmt.2009.259
  46. Pfaller MA, Diekema DJ, Gibbs DL, et al. Results from the ARTEMIS DISK Global Antifungal Surveillance study, 1997 to 2005: an 8.5-year analysis of susceptibilities of Candida species and other yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing. J Clin Microbiol 2007;45:1735-1745. https://doi.org/10.1128/JCM.00409-07
  47. Pfaller MA, Messer SA, Boyken L, Tendolkar S, Hollis RJ, Diekema DJ. Geographic variation in the susceptibilities of invasive isolates of Candida glabrata to seven systemically active antifungal agents: a global assessment from the ARTEMIS Antifungal Surveillance Program conducted in 2001 and 2002. J Clin Microbiol 2004;42:3142-3146. https://doi.org/10.1128/JCM.42.7.3142-3146.2004
  48. Van Burik JA, Ratanatharathorn V, Stepan DE, et al. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis 2004;39:1407-1416. https://doi.org/10.1086/422312
  49. Matsue K, Uryu H, Koseki M, Asada N, Takeuchi M. Breakthrough trichosporonosis in patients with hematologic malignancies receiving micafungin. Clin Infect Dis 2006; 42:753-757. https://doi.org/10.1086/500323
  50. Madureira A, Bergeron A, Lacroix C, et al. Breakthrough invasive aspergillosis in allogeneic haematopoietic stem cell transplant recipients treated with caspofungin. Int J Antimicrob Agents 2007;30:551-554. https://doi.org/10.1016/j.ijantimicag.2007.07.026
  51. Oren I, Rowe JM, Sprecher H, et al. A prospective randomized trial of itraconazole vs fluconazole for the prevention of fungal infections in patients with acute leukemia and hematopoietic stem cell transplant recipients. Bone Marrow Transplant 2006;38:127-134. https://doi.org/10.1038/sj.bmt.1705418
  52. Winston DJ, Maziarz RT, Chandrasekar PH, et al. Intra-venous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients: a multicenter, randomized trial. Ann Intern Med 2003;138: 705-713. https://doi.org/10.7326/0003-4819-138-9-200305060-00006
  53. Marr KA, Crippa F, Leisenring W, et al. Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood 2004;103: 1527-1533.
  54. Hof H. A new, broad-spectrum azole antifungal: posaconazole: mechanisms of action and resistance, spectrum of activity. Mycoses 2006;49(Suppl 1):S2-S6. https://doi.org/10.1111/j.1439-0507.2006.01295.x
  55. Boucher HW, Groll AH, Chiou CC, Walsh TJ. Newer systemic antifungal agents: pharmacokinetics, safety and efficacy. Drugs 2004;64:1997-2020. https://doi.org/10.2165/00003495-200464180-00001
  56. Ullmann AJ, Lipton JH, Vesole DH, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007;356:335-347. https://doi.org/10.1056/NEJMoa061098
  57. De la Camara R, Jarque I, Sanz MA, et al. Economic evaluation of posaconazole vs fluconazole in the prevention of invasive fungal infections in patients with GVHD following haematopoietic SCT. Bone Marrow Transplant 2010;45:925-932. https://doi.org/10.1038/bmt.2009.272
  58. O'Sullivan AK, Weinstein MC, Pandya A, et al. Costeffectiveness of posaconazole versus fluconazole for prevention of invasive fungal infections in U.S. patients with graft-versus-host disease. Am J Health Syst Pharm 2012;69:149-156. https://doi.org/10.2146/ajhp110149
  59. Ananda-Rajah MR, Grigg A, Slavin MA. Making sense of posaconazole therapeutic drug monitoring: a practical approach. Curr Opin Infect Dis 2012;25:605-611. https://doi.org/10.1097/QCO.0b013e328359a56e
  60. Cordonnier C, Rovira M, Maertens J, Cornely OA, Ljungman P, Einsele H. Voriconazole as secondary antifungal prophylaxis in stem cell transplant recipients. Haematologica 2011;96:e9-e10. https://doi.org/10.3324/haematol.2010.038463
  61. Cordonnier C, Rovira M, Maertens J, et al. Voriconazole for secondary prophylaxis of invasive fungal infections in allogeneic stem cell transplant recipients: results of the VOSIFI Study. Haematologica 2010;95:1762-1768. https://doi.org/10.3324/haematol.2009.020073
  62. Pappas PG, Alexander BD, Andes DR, et al. Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). Clin Infect Dis 2010;50:1101-1111. https://doi.org/10.1086/651262
  63. Winston DJ, Pakrasi A, Busuttil RW. Prophylactic fluconazole in liver transplant recipients: a randomized, doubleblind, placebo-controlled trial. Ann Intern Med 1999;131: 729-737.
  64. Lumbreras C, Cuervas-Mons V, Jara P, et al. Randomized trial of fluconazole versus nystatin for the prophylaxis of Candida infection following liver transplantation. J Infect Dis 1996;174:583-588. https://doi.org/10.1093/infdis/174.3.583
  65. Cruciani M, Mengoli C, Malena M, Bosco O, Serpelloni G, Grossi P. Antifungal prophylaxis in liver transplant patients: a systematic review and meta-analysis. Liver Transpl 2006;12:850-858. https://doi.org/10.1002/lt.20690
  66. Playford EG, Webster AC, Sorell TC, Craig JC. Antifungal agents for preventing fungal infections in solid organ transplant recipients. Cochrane Database Syst Rev 2004: CD004291.
  67. Hadley S, Huckabee C, Pappas PG, et al. Outcomes of antifungal prophylaxis in high-risk liver transplant recipients. Transpl Infect Dis 2009;11:40-48. https://doi.org/10.1111/j.1399-3062.2008.00361.x
  68. Playford EG, Webster AC, Sorrell TC, Craig JC. Systematic review and meta-analysis of antifungal agents for preventing fungal infections in liver transplant recipients. Eur J Clin Microbiol Infect Dis 2006;25:549-561. https://doi.org/10.1007/s10096-006-0182-3
  69. Brizendine KD, Vishin S, Baddley JW. Antifungal prophylaxis in solid organ transplant recipients. Expert Rev Anti Infect Ther 2011;9:571-581. https://doi.org/10.1586/eri.11.29
  70. Munoz P, Rodriguez C, Bouza E, et al. Risk factors of invasive aspergillosis after heart transplantation: protective role of oral itraconazole prophylaxis. Am J Transplant 2004;4:636-643. https://doi.org/10.1111/j.1600-6143.2004.00390.x
  71. Biancofiore G, Bindi ML, Baldassarri R, et al. Antifungal prophylaxis in liver transplant recipients: a randomized placebo-controlled study. Transpl Int 2002;15:341-347. https://doi.org/10.1111/j.1432-2277.2002.tb00176.x
  72. Winston DJ, Busuttil RW. Randomized controlled trial of oral itraconazole solution versus intravenous/oral fluconazole for prevention of fungal infections in liver transplant recipients. Transplantation 2002;74:688-695. https://doi.org/10.1097/00007890-200209150-00017
  73. Sharpe MD, Ghent C, Grant D, Horbay GL, McDougal J, David Colby W. Efficacy and safety of itraconazole prophylaxis for fungal infections after orthotopic liver transplantation: a prospective, randomized, double-blind study. Transplantation 2003;76:977-983. https://doi.org/10.1097/01.TP.0000085653.11565.52
  74. Drew RH, Dodds Ashley E, Benjamin DK Jr, Duane Davis R, Palmer SM, Perfect JR. Comparative safety of amphotericin B lipid complex and amphotericin B deoxycholate as aerosolized antifungal prophylaxis in lung-transplant recipients. Transplantation 2004;77:232-237. https://doi.org/10.1097/01.TP.0000101516.08327.A9
  75. Drew R. Potential role of aerosolized amphotericin B formulations in the prevention and adjunctive treatment of invasive fungal infections. Int J Antimicrob Agents 2006; 27(Suppl 1):36-44. https://doi.org/10.1016/j.ijantimicag.2006.03.018
  76. Akan H, Arslan O, Akan OA. Tuberculosis in stem cell transplant patients. J Hosp Infect 2006;62:421-426. https://doi.org/10.1016/j.jhin.2005.09.020
  77. Yuen KY, Woo PC. Tuberculosis in blood and marrow transplant recipients. Hematol Oncol 2002;20:51-62. https://doi.org/10.1002/hon.681
  78. Joint Committee for the Development of Korean Guidelines for Tuberculosis, Korea Centers for Disease Control and Prevention. Korean Guidelines for Tuberculosis. 2011:1-218.
  79. Torre-Cisneros J, Doblas A, Aguado JM, et al. Tuberculosis after solid-organ transplant: incidence, risk factors, and clinical characteristics in the RESITRA (Spanish Network of Infection in Transplantation) Cohort. Clin Infect Dis 2009;48:1657-1665. https://doi.org/10.1086/599035
  80. Ha YE, Joo EJ, Park SY, et al. Tacrolimus as a risk factor for tuberculosis and outcome of treatment with rifampicin in solid organ transplant recipients. Transpl Infect Dis 2012; 14:626-634. https://doi.org/10.1111/j.1399-3062.2012.00721.x
  81. Munoz P, Rodriguez C, Bouza E. Mycobacterium tuberculosis infection in recipients of solid organ transplants. Clin Infect Dis 2005;40:581-587. https://doi.org/10.1086/427692
  82. Ljungman P, Fridell E, Lönnqvist B, et al. Efficacy and safety of vaccination of marrow transplant recipients with a live attenuated measles, mumps, and rubella vaccine. J Infect Dis 1989;159:610-615. https://doi.org/10.1093/infdis/159.4.610
  83. Ljungman P, Wiklund-Hammarsten M, Duraj V, et al. Response to tetanus toxoid immunization after allogeneic bone marrow transplantation. J Infect Dis 1990;162:496-500. https://doi.org/10.1093/infdis/162.2.496
  84. Pauksen K, Duraj V, Ljungman P, et al. Immunity to and immunization against measles, rubella and mumps in patients after autologous bone marrow transplantation. Bone Marrow Transplant 1992;9:427-432.
  85. Parkman R, Weinberg K. Immunological reconstitution following hematopoietic stem cell transplantation. In: Blume K,Forman S, Appelbaum F, eds. Thomas's Hematopoietic Cell Transplantation. 3rd edition Malden: Blackwell Science; 2003: 853-861.
  86. Storek J, Witherspoon RP. Immunological reconstitution after hematopoietic stem cell transplantation. In: Atkinson K, Champlin R, Ritz J, Fibbe WE, Ljungman P, Brenner MK, eds. Clinical Bone Marrow and Blood Stem Cell Transplantation. 3rd edition. Cambridge: Cambridge University Press, 2004:194-226.
  87. Molrine DC, Antin JH, Guinan EC, et al. Donor immunization with pneumococcal conjugate vaccine and early protective antibody responses following allogeneic hematopoietic cell transplantation. Blood 2003;101:831-836. https://doi.org/10.1182/blood-2002-03-0832
  88. Molrine DC, Guinan EC, Antin JH, et al. Donor immunization with Haemophilus influenzae type b (HIB)-conjugate vaccine in allogeneic bone marrow transplantation. Blood 1996;87:3012-3018.
  89. Guinan EC, Molrine DC, Antin JH, et al. Polysaccharide conjugate vaccine responses in bone marrow transplant patients. Transplantation 1994;57:677-684. https://doi.org/10.1097/00007890-199403150-00009
  90. Kumar D, Chen MH, Welsh B, et al. A randomized, double-blind trial of pneumococcal vaccination in adult allogeneic stem cell transplant donors and recipients. Clin Infect Dis 2007;45:1576-1582. https://doi.org/10.1086/523583
  91. Cordonnier C, Labopin M, Chesnel V, et al. Randomized study of early versus late immunization with pneumococcal conjugate vaccine after allogeneic stem cell transplantation. Clin Infect Dis 2009;48:1392-1401. https://doi.org/10.1086/598324
  92. Cordonnier C, Labopin M, Chesnel V, et al. Immune response to the 23-valent polysaccharide pneumococcal vaccine after the 7-valent conjugate vaccine in allogeneic stem cell transplant recipients: results from the EBMT IDWP01 trial. Vaccine 2010;28:2730-2734. https://doi.org/10.1016/j.vaccine.2010.01.025
  93. Danzinger-Isakov L, Kumar D; AST Infectious Diseases Community of Practice. Guidelines for vaccination of solid organ transplant candidates and recipients. Am J Transplant 2009;9(Suppl 4):S258-S262. https://doi.org/10.1111/j.1600-6143.2009.02917.x
  94. Cordero E, Manuel O. Influenza vaccination in solid-organ transplant recipients. Curr Opin Organ Transplant 2012;17: 601-608. https://doi.org/10.1097/MOT.0b013e3283592622

Cited by

  1. 신장이식 환자의 인플루엔자 예방접종 실태와 이행 영향 요인 vol.18, pp.2, 2013, https://doi.org/10.7586/jkbns.2016.18.2.118